moatshark My

All holdings

Thermo Fisher Scientific

TMO

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
8
In their latest 13F (Q3 2026)
See who
Value held
$2.0bn
Combined value at quarter end
Last quarter
3 bought
4 sold or trimmed
Fund portfolios
4
Funds holding it
See which
Price at Q3 ’26 end
$675.06
+34.6% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-15.9%Q4 ’24
-4.4%Q1 ’25
-18.5%Q2 ’25
+19.6%Q3 ’25
+19.5%Q4 ’25
-15.2%Q1 ’26
+2.0%Q2 ’26
+34.6%Q3 ’26
Q4 ’24: -15.9%; Q1 ’25: -4.4%; Q2 ’25: -18.5%; Q3 ’25: +19.6%; Q4 ’25: +19.5%; Q1 ’26: -15.2%; Q2 ’26: +2.0%; Q3 ’26: +34.6%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

9Q4 ’23
9Q1 ’24
8Q2 ’24
8Q3 ’24
9Q4 ’24
9Q1 ’25
10Q2 ’25
11Q3 ’25
11Q4 ’25
9Q1 ’26
8Q2 ’26
1Q3 ’26
Q4 ’23: 9; Q1 ’24: 9; Q2 ’24: 8; Q3 ’24: 8; Q4 ’24: 9; Q1 ’25: 9; Q2 ’25: 10; Q3 ’25: 11; Q4 ’25: 11; Q1 ’26: 9; Q2 ’26: 8; Q3 ’26: 1

Counts the managers on this site whose 13F for that quarter includes Thermo Fisher Scientific.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Thermo Fisher Scientific
Lindsell Train9.8%$258m$258mTrimmed -17%7 qtrs
Weitz Investment Management4.0%$57.8m$57.8mTrimmed -4.8%39 qtrs
First Pacific Advisors (FPA)1.5%$124m$124mAdded +12%5 qtrs
Matrix Asset Advisors1.3%$16.2m$16.2mTrimmed -13%54 qtrs
Dodge & Cox0.8%$1.5bn$1.5bnAdded +11767%53 qtrs
Markel Group0.3%$36.6m$36.6mAdded +8.9%19 qtrs
Mairs & Power0.0%$622k$622kUnchanged50 qtrs
Horizon Kinetics0.0%$220k$220kUnchanged4 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Thermo Fisher Scientific
Bought or soldFiling
31 Aug 2026Pettiti GianlucaPresident & COO▼ Sold3,733$614.38$2.3mForm 4
31 Aug 2026Pettiti GianlucaPresident & COO▼ Sold400$614.38$246kForm 4
24 Aug 2026Casper Marc NChairman & CEO▼ Sold101$625.41$63kForm 4
24 Aug 2026Casper Marc NChairman & CEO▼ Sold79$628.01$50kForm 4
24 Aug 2026Casper Marc NChairman & CEO▼ Sold62$628.74$39kForm 4
24 Aug 2026Casper Marc NChairman & CEO▼ Sold33$626.59$21kForm 4
21 Aug 2026Casper Marc NChairman & CEO▼ Sold3,014$626.51$1.9mForm 4
21 Aug 2026Casper Marc NChairman & CEO▼ Sold2,727$625.46$1.7mForm 4
21 Aug 2026Casper Marc NChairman & CEO▼ Sold2,147$628.61$1.3mForm 4
21 Aug 2026Casper Marc NChairman & CEO▼ Sold1,791$627.39$1.1mForm 4
21 Aug 2026Casper Marc NChairman & CEO▼ Sold321$629.10$202kForm 4
20 Aug 2026Casper Marc NChairman & CEO▼ Sold2,601$628.82$1.6mForm 4
20 Aug 2026Casper Marc NChairman & CEO▼ Sold1,430$632.01$904kForm 4
20 Aug 2026Casper Marc NChairman & CEO▼ Sold1,314$627.66$825kForm 4
20 Aug 2026Casper Marc NChairman & CEO▼ Sold1,250$629.85$787kForm 4
20 Aug 2026Casper Marc NChairman & CEO▼ Sold1,035$630.87$653kForm 4
20 Aug 2026Casper Marc NChairman & CEO▼ Sold909$625.45$569kForm 4
20 Aug 2026Casper Marc NChairman & CEO▼ Sold821$626.83$515kForm 4
20 Aug 2026Casper Marc NChairman & CEO▼ Sold560$632.94$354kForm 4
20 Aug 2026Casper Marc NChairman & CEO▼ Sold80$633.99$51kForm 4

About the company

Sector
Technology · Measuring & Controlling Devices, Nec
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
370m at 27 Jun 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$13bn2013
$17bn2015
$21bn2017
$26bn2019
$39bn2021
$43bn2023
$45bn2025
2013: $13bn; 2014: $17bn; 2015: $17bn; 2016: $18bn; 2017: $21bn; 2018: $24bn; 2019: $26bn; 2020: $32bn; 2021: $39bn; 2022: $45bn; 2023: $43bn; 2024: $43bn; 2025: $45bn
Thermo Fisher Scientific revenue and net income by year
YearRevenueNet income
2025$45bn$6.7bn
2024$43bn$6.3bn
2023$43bn$6.0bn
2022$45bn$7.0bn
2021$39bn$7.7bn
2020$32bn–
2019$26bn–
2018$24bn–
2017$21bn–
2016$18bn–
2015$17bn–
2014$17bn–
2013$13bn$1.3bn

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

Sold out last quarter

In fund portfolios

US-registered funds run by these managers that hold Thermo Fisher Scientific, from their latest N-PORT filings.

Funds holding Thermo Fisher Scientific
Weitz Large Cap Equity FundWeitz Investment Management5.8%$36.6m30 Jun 2026
Weitz Partners III Opportunity FundWeitz Investment Management4.8%$16.0m30 Jun 2026
FPA Crescent FundFirst Pacific Advisors (FPA)0.6%$75.3m30 Jun 2026
Dodge & Cox Global Stock FundDodge & Cox0.5%$68.7m30 Jun 2026